EPA-0685 – Guanfacine XR (GXR) for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): phase 3, randomized, double-blind, multicenter, placebo- and active-reference study
Amaia Hervás(Mútua Terrassa), Brigitte Robertson(Takeda (United States)), A. G. Lyne(University of Manchester), Sasha Sreckovic, Fiona McNicholas(University College Dublin), Ralph Bloomfield(AstraZeneca (United Kingdom)), Judy van Stralen(Ontario Centre of Excellence for Child and Youth Mental Health), Mats Johnson(Sahlgrenska University Hospital), Vanja Sikirica(Moderna Therapeutics (United States))
Cited by 3
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Computerized Training of Working Memory in Children With ADHD-A Randomized, Controlled Trial
|Journal of the American Academy of Child & Adolescent Psychiatry|2005|2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Certolizumab Pegol for the Treatment of Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Tests of General Relativity from Timing the Double Pulsar
|Science|2006|1.1k